Mr. Yunji Kim reports
EASTWOOD BIO-MEDICAL CANADA INC. ANNOUNCES REFILING OF ITS ANNUAL AND INTERIM MD&A
As a result of a review by the B.C. Securities Commission, Eastwood Bio-Medical Canada Inc. is issuing this press release to clarify its
disclosure.
With respect to the company's annual management's discussion and analysis for the year ended
Oct. 31, 2025, and its interim management's discussion and analysis
for the nine-month period ended July 31, 2026, the BCSC has concluded that the affected filings lack
sufficient discussion as per the requirements of Form 51-102F1. As a result, the company has
amended and refiled the affected filings.
The affected filings clarify the company's supply and manufacturing arrangements, expand the
disclosure of related-party relationships and balances, and strengthen the discussion of liquidity
and financing needs. They also provide more detail on the factors affecting revenue and gross
margin, add disclosure of recent strategic agreements, and make minor corrections and formatting
updates throughout.
The amended and restated affected filings have been filed on SEDAR+. The
amended and restated affected filings replace and supersede the corresponding financial
statements and MD&A previously filed by the company. Readers should rely only on the amended
and restated affected filings now available on SEDAR+.
© 2026 Canjex Publishing Ltd. All rights reserved.